Bristol Myers Squibb Faces Steep Patent Cliff
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 21 2026
0mins
Source: Fool
- Patent Cliff Impact: Bristol Myers Squibb faces an unusually steep patent cliff, with Revlimid sales projected to decline by 48.9% to $2.9 billion in 2025 and Sprycel sales dropping 61.7% to $493 million, directly impacting revenue and market confidence.
- Key Drug Patent Expirations: The combined sales of top drugs Eliquis and Opdivo are expected to reach $24.4 billion in 2025, accounting for nearly half of total revenue, with U.S. patent protection expiring between 2027 and 2029, leading to fierce generic competition.
- New Drug Development Potential: Despite challenges, Bristol Myers Squibb's growth portfolio saw a 23% sales increase to $16.3 billion in 2025, with Cobenfy, an innovative antipsychotic, potentially achieving $3.4 billion in annual sales by 2030 if FDA approved, which could offset future revenue losses.
- Dividend Appeal: The company currently offers a 4.2% dividend yield, with payouts consuming less than half of earnings, indicating financial stability, and providing investors with steady cash flow even amidst the looming patent cliff.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BMY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BMY
Wall Street analysts forecast BMY stock price to fall
20 Analyst Rating
8 Buy
11 Hold
1 Sell
Moderate Buy
Current: 57.180
Low
37.00
Averages
55.86
High
68.00
Current: 57.180
Low
37.00
Averages
55.86
High
68.00
About BMY
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development, and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Orencia (abatacept), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Breyanzi (lisocabtagene maraleucel), Opdualag (nivolumab and relatlimab-rmbw), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), Sotyktu (deucravacitinib), Krazati (adagrasib), and Cobenfy (xanomeline and trospium chloride). Its other growth products include Augtyro, Onureg, Inrebic, Nulojix, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
FDA Grants Priority Review for BMS's Camzyos in Adolescents
- New Drug Application Approved: The US FDA has accepted Bristol Myers Squibb's sNDA for Camzyos (mavacamten) targeting symptomatic obstructive hypertrophic cardiomyopathy in adolescents and granted Priority Review, which, if approved, would make it the first cardiac myosin inhibitor for this condition, addressing a significant market need.
- Clinical Trial Support: The application is backed by data from the phase 3 SCOUT-HCM trial, which demonstrated a statistically significant reduction in the Valsalva left ventricular outflow tract (LVOT) gradient at week 28 in the Camzyos group compared to placebo, confirming its efficacy.
- Significant Market Potential: Hypertrophic cardiomyopathy leads to reduced exertional tolerance and higher morbidity in adolescents, and the approval of Camzyos would provide a new treatment option for this demographic, potentially improving their quality of life significantly.
- Strategic Implications: Bristol Myers Squibb's innovative drug development in the cardiology space highlights its leadership in the biopharmaceutical industry and could usher in a new growth cycle for the company, further solidifying its market position.
See More
Ivonescimab Data Enhances Market Prospects Against Keytruda
- Survival Extension: The Phase 3 Harmoni-6 study presented at ASCO demonstrated that Ivonescimab combined with chemotherapy extended median overall survival from 23.7 months to 27.9 months, with nearly 65% of patients alive after two years, significantly enhancing its market competitiveness.
- Intensifying Industry Competition: The success of Ivonescimab has heightened pressure on major pharmaceutical players like Pfizer (PFE), Bristol Myers Squibb (BMY), and Merck (MRK), all of whom are advancing rival therapies, particularly in light of the impending patent cliff.
- FDA Review Progress: Summit Therapeutics has submitted an FDA application for Ivonescimab plus chemotherapy in EGFR-mutated lung cancer, with a regulatory decision expected by November 14, positioning the company advantageously in the competitive landscape.
- Investor Sentiment Rebound: Retail investor sentiment for SMMT surged to an all-time high of 97/100 on Stocktwits, with message volume increasing by over 9,200%, reflecting strong market confidence in the future potential of Ivonescimab.
See More
First PD-(L)1xVEGF Bispecific Immunomodulator Shows Promising Efficacy in NSCLC
- Clinical Trial Results: The global ROSETTA Lung-02 trial demonstrated that Pumitamig combined with chemotherapy achieved objective response rates of 57.1% in non-squamous and 68.4% in squamous non-small cell lung cancer patients, indicating robust anti-tumor activity across various PD-L1 expression levels.
- Dose Optimization Effects: At the lower dose, Pumitamig showed objective response rates of 63.6% for non-squamous and 72.7% for squamous NSCLC, highlighting a dose-dependent efficacy that may offer better treatment options for patients.
- Safety Analysis: The clinical trial reported a manageable safety profile for Pumitamig, with grade ≥ 3 treatment-related adverse events occurring in 48.8% of patients, of which 23.3% were deemed related to Pumitamig, indicating its controllability in clinical applications.
- Future Development Plans: BioNTech and Bristol Myers Squibb are advancing a broad development plan for Pumitamig, aiming to evaluate its efficacy in various stages of non-small cell lung cancer across multiple clinical trials, with the goal of improving existing treatment standards.
See More
C4 Therapeutics Hits 52-Week High Following BMY's Positive Myeloma Trial Results
- Impressive Survival Data: Bristol-Myers Squibb's (BMY) late-stage SUCCESSOR-2 trial for its multiple myeloma candidate mezigdomide demonstrated over a 50% improvement in cancer-free survival, positively impacting C4 Therapeutics (CCCC) stock performance.
- Strong Market Reaction: Following BMY's announcement, C4 Therapeutics' stock surged to a 52-week high, indicating increased investor confidence in its lead candidate cemsidomide, particularly given the similarities in treatment strategies.
- Future Data Sharing Plans: C4 plans to present data from a Phase 1b trial evaluating cemsidomide in combination with approved multiple myeloma therapies in H2 2026, which will further support its market prospects.
- Analyst Optimism: Jefferies analyst Akash Tewari expressed a positive outlook for C4, suggesting that BMY's favorable data will have a beneficial read-through for C4, maintaining a Buy rating on the stock, reflecting market recognition of its growth potential.
See More
Bristol Myers Squibb's Antitumor Drug Trial Shows Promising Results
- Clinical Trial Success: Bristol Myers Squibb's antitumor candidate mezigdomide improved cancer-free survival by over 50% in a late-stage trial for multiple myeloma, demonstrating significant clinical and statistical relevance.
- Patient Data Analysis: In the open-label Phase 3 SUCCESSOR-2 trial, 479 patients were enrolled, and the mezigdomide-containing regimen reduced the risk of disease progression or death by 52% compared to the standard treatment.
- Safety Assessment: While mezigdomide showed a safety profile consistent with past data, 83.7% of patients experienced Grade 3 or 4 treatment-emergent adverse events, compared to 56.5% in the comparator arm, indicating a higher incidence of side effects.
- Future Outlook: Data from the SUCCESSOR-2 trial will be presented at the ASCO 2026 meeting and is set to be submitted to health regulators, further enhancing the market potential of this therapy.
See More
Bristol-Myers Squibb Phase 3 Trial Results
See More
FDA Grants Priority Review for BMS's Camzyos in Adolescents
- New Drug Application Approved: The US FDA has accepted Bristol Myers Squibb's sNDA for Camzyos (mavacamten) targeting symptomatic obstructive hypertrophic cardiomyopathy in adolescents and granted Priority Review, which, if approved, would make it the first cardiac myosin inhibitor for this condition, addressing a significant market need.
- Clinical Trial Support: The application is backed by data from the phase 3 SCOUT-HCM trial, which demonstrated a statistically significant reduction in the Valsalva left ventricular outflow tract (LVOT) gradient at week 28 in the Camzyos group compared to placebo, confirming its efficacy.
- Significant Market Potential: Hypertrophic cardiomyopathy leads to reduced exertional tolerance and higher morbidity in adolescents, and the approval of Camzyos would provide a new treatment option for this demographic, potentially improving their quality of life significantly.
- Strategic Implications: Bristol Myers Squibb's innovative drug development in the cardiology space highlights its leadership in the biopharmaceutical industry and could usher in a new growth cycle for the company, further solidifying its market position.
See More
Ivonescimab Data Enhances Market Prospects Against Keytruda
- Survival Extension: The Phase 3 Harmoni-6 study presented at ASCO demonstrated that Ivonescimab combined with chemotherapy extended median overall survival from 23.7 months to 27.9 months, with nearly 65% of patients alive after two years, significantly enhancing its market competitiveness.
- Intensifying Industry Competition: The success of Ivonescimab has heightened pressure on major pharmaceutical players like Pfizer (PFE), Bristol Myers Squibb (BMY), and Merck (MRK), all of whom are advancing rival therapies, particularly in light of the impending patent cliff.
- FDA Review Progress: Summit Therapeutics has submitted an FDA application for Ivonescimab plus chemotherapy in EGFR-mutated lung cancer, with a regulatory decision expected by November 14, positioning the company advantageously in the competitive landscape.
- Investor Sentiment Rebound: Retail investor sentiment for SMMT surged to an all-time high of 97/100 on Stocktwits, with message volume increasing by over 9,200%, reflecting strong market confidence in the future potential of Ivonescimab.
See More
First PD-(L)1xVEGF Bispecific Immunomodulator Shows Promising Efficacy in NSCLC
- Clinical Trial Results: The global ROSETTA Lung-02 trial demonstrated that Pumitamig combined with chemotherapy achieved objective response rates of 57.1% in non-squamous and 68.4% in squamous non-small cell lung cancer patients, indicating robust anti-tumor activity across various PD-L1 expression levels.
- Dose Optimization Effects: At the lower dose, Pumitamig showed objective response rates of 63.6% for non-squamous and 72.7% for squamous NSCLC, highlighting a dose-dependent efficacy that may offer better treatment options for patients.
- Safety Analysis: The clinical trial reported a manageable safety profile for Pumitamig, with grade ≥ 3 treatment-related adverse events occurring in 48.8% of patients, of which 23.3% were deemed related to Pumitamig, indicating its controllability in clinical applications.
- Future Development Plans: BioNTech and Bristol Myers Squibb are advancing a broad development plan for Pumitamig, aiming to evaluate its efficacy in various stages of non-small cell lung cancer across multiple clinical trials, with the goal of improving existing treatment standards.
See More
C4 Therapeutics Hits 52-Week High Following BMY's Positive Myeloma Trial Results
- Impressive Survival Data: Bristol-Myers Squibb's (BMY) late-stage SUCCESSOR-2 trial for its multiple myeloma candidate mezigdomide demonstrated over a 50% improvement in cancer-free survival, positively impacting C4 Therapeutics (CCCC) stock performance.
- Strong Market Reaction: Following BMY's announcement, C4 Therapeutics' stock surged to a 52-week high, indicating increased investor confidence in its lead candidate cemsidomide, particularly given the similarities in treatment strategies.
- Future Data Sharing Plans: C4 plans to present data from a Phase 1b trial evaluating cemsidomide in combination with approved multiple myeloma therapies in H2 2026, which will further support its market prospects.
- Analyst Optimism: Jefferies analyst Akash Tewari expressed a positive outlook for C4, suggesting that BMY's favorable data will have a beneficial read-through for C4, maintaining a Buy rating on the stock, reflecting market recognition of its growth potential.
See More
Bristol Myers Squibb's Antitumor Drug Trial Shows Promising Results
- Clinical Trial Success: Bristol Myers Squibb's antitumor candidate mezigdomide improved cancer-free survival by over 50% in a late-stage trial for multiple myeloma, demonstrating significant clinical and statistical relevance.
- Patient Data Analysis: In the open-label Phase 3 SUCCESSOR-2 trial, 479 patients were enrolled, and the mezigdomide-containing regimen reduced the risk of disease progression or death by 52% compared to the standard treatment.
- Safety Assessment: While mezigdomide showed a safety profile consistent with past data, 83.7% of patients experienced Grade 3 or 4 treatment-emergent adverse events, compared to 56.5% in the comparator arm, indicating a higher incidence of side effects.
- Future Outlook: Data from the SUCCESSOR-2 trial will be presented at the ASCO 2026 meeting and is set to be submitted to health regulators, further enhancing the market potential of this therapy.
See More
Bristol-Myers Squibb Phase 3 Trial Results
See More
